JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for
JJP Biologics a private biopharmaceutical company developing innovative antibodybased therapies announces a positive decision issued by the European Medicines Agency on the Clinical Trial Application to conduct a phase I clinical study in healthy participants EudraCT 20235086613300 with their potential firstinclass antiCD89 antagonist JJP1212.
Immunocore Holdings plc: Immunocore reports first quarter financial results and provides a business update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Immunocore reports first quarter financial results and provides a business update tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.